Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents

F. Millot, C. Dupraz, J. Guilhot, M. Suttorp, F. Brizard, T. Leblanc, AM. Güneş, P. Sedlacek, E. De Bont, CK. Li, K. Kalwak, B. Lausen, S. Culic, M. Dworzak, E. Kaiserova, B. De Moerloose, F. Roula, A. Biondi, A. Baruchel, F. Guilhot,

. 2017 ; 123 (18) : 3609-3616. [pub] 20170512

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18016611

BACKGROUND: In the adult population with newly diagnosed chronic myeloid leukemia (CML), variant translocations are usually not considered to be impairing the prognosis, whereas some additional cytogenetic abnormalities (ACAs) are associated with a negative impact on survival. Because of the rarity of CML in the pediatric population, such abnormalities have not been investigated in a large group of children with CML. METHODS: The prognostic relevance of variant t(9;22) and ACAs at diagnosis was assessed in 301 children with CML in the chronic phase who were enrolled in the International Registry for Chronic Myeloid Leukemia in Children and Adolescents. RESULTS: Overall, 19 children (6.3%) presented with additional cytogenetic findings at diagnosis: 5 children (1.7%) had a variant t(9;22) translocation, 13 children (4.3%) had ACAs, and 1 had both. At 3 years, for children with a classic translocation, children with ACAs, and children with a variant t(9;22) translocation who were treated with imatinib as frontline therapy, the probability of progression-free survival (PFS) was 95% (95% confidence interval [CI], 91%-97%), 100%, and 75% (95% CI, 13%-96%), respectively, and the probability of overall survival (OS) was 98% (95% CI, 95%-100%), 100% (95% CI, 43%-98%), and 75% (95% CI, 13%-96%), respectively. No statistical difference was observed between the patients with classic cytogenetic findings and those with additional chromosomal abnormalities in terms of PFS and OS. CONCLUSIONS: In contrast to adults with CML, additional chromosomal abnormalities observed at diagnosis do not seem to have a significant prognostic impact. Cancer 2017;123:3609-16. © 2017 American Cancer Society.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016611
003      
CZ-PrNML
005      
20180516110334.0
007      
ta
008      
180515s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cncr.30767 $2 doi
035    __
$a (PubMed)28497898
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Millot, Frédéric $u INSERM Clinical Investigation Center 1402, Poitiers University, Poitiers, France.
245    10
$a Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents / $c F. Millot, C. Dupraz, J. Guilhot, M. Suttorp, F. Brizard, T. Leblanc, AM. Güneş, P. Sedlacek, E. De Bont, CK. Li, K. Kalwak, B. Lausen, S. Culic, M. Dworzak, E. Kaiserova, B. De Moerloose, F. Roula, A. Biondi, A. Baruchel, F. Guilhot,
520    9_
$a BACKGROUND: In the adult population with newly diagnosed chronic myeloid leukemia (CML), variant translocations are usually not considered to be impairing the prognosis, whereas some additional cytogenetic abnormalities (ACAs) are associated with a negative impact on survival. Because of the rarity of CML in the pediatric population, such abnormalities have not been investigated in a large group of children with CML. METHODS: The prognostic relevance of variant t(9;22) and ACAs at diagnosis was assessed in 301 children with CML in the chronic phase who were enrolled in the International Registry for Chronic Myeloid Leukemia in Children and Adolescents. RESULTS: Overall, 19 children (6.3%) presented with additional cytogenetic findings at diagnosis: 5 children (1.7%) had a variant t(9;22) translocation, 13 children (4.3%) had ACAs, and 1 had both. At 3 years, for children with a classic translocation, children with ACAs, and children with a variant t(9;22) translocation who were treated with imatinib as frontline therapy, the probability of progression-free survival (PFS) was 95% (95% confidence interval [CI], 91%-97%), 100%, and 75% (95% CI, 13%-96%), respectively, and the probability of overall survival (OS) was 98% (95% CI, 95%-100%), 100% (95% CI, 43%-98%), and 75% (95% CI, 13%-96%), respectively. No statistical difference was observed between the patients with classic cytogenetic findings and those with additional chromosomal abnormalities in terms of PFS and OS. CONCLUSIONS: In contrast to adults with CML, additional chromosomal abnormalities observed at diagnosis do not seem to have a significant prognostic impact. Cancer 2017;123:3609-16. © 2017 American Cancer Society.
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a chromozomální aberace $x statistika a číselné údaje $7 D002869
650    _2
$a lidské chromozomy, pár 22 $x genetika $7 D002892
650    _2
$a lidské chromozomy, pár 9 $x genetika $7 D002899
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a následné studie $7 D005500
650    _2
$a genetická predispozice k nemoci $x epidemiologie $7 D020022
650    _2
$a lidé $7 D006801
650    _2
$a internacionalita $7 D038622
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a chronická myeloidní leukemie $x diagnóza $x farmakoterapie $x genetika $x mortalita $7 D015464
650    _2
$a kvantitativní polymerázová řetězová reakce $x metody $7 D060888
650    _2
$a registrace $7 D012042
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a neparametrická statistika $7 D018709
650    _2
$a analýza přežití $7 D016019
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dupraz, Christelle $u INSERM Clinical Investigation Center 1402, Poitiers University, Poitiers, France.
700    1_
$a Guilhot, Joelle $u INSERM Clinical Investigation Center 1402, Poitiers University, Poitiers, France.
700    1_
$a Suttorp, Meinolf $u Department of Pediatrics, Carl Gustav Carus University Hospital, Dresden, Germany.
700    1_
$a Brizard, Françoise $u INSERM Clinical Investigation Center 1402, Poitiers University, Poitiers, France.
700    1_
$a Leblanc, Thierry $u Department of Pediatric Hematology, Robert Debré Hospital, Paris, France.
700    1_
$a Güneş, Adalet Meral $u Department of Pediatric Hematology, Uludağ University Hospital, Görükle Bursa, Turkey.
700    1_
$a Sedlacek, Petr $u Department of Pediatric Hematology-Oncology, Motol University Hospital, Charles University, Prague, Czech Republic.
700    1_
$a De Bont, Evelyne $u Department of Pediatric Oncology-Hematology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Dutch Childhood Oncology Group, the Hague, the Netherlands.
700    1_
$a Li, Chi Kong $u Department of Pediatrics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China.
700    1_
$a Kalwak, Krzysztof $u Department of Pediatric Hematology-Oncology and Transplantation, Wroclaw Medical University, Wroclaw, Poland.
700    1_
$a Lausen, Birgitte $u Department of Pediatrics, Rigshospitalet, University Hospital, Copenhagen, Denmark.
700    1_
$a Culic, Srdjana $u Department of Pediatric Hematology, Oncology, Immunology, and Medical Genetics, Clinical Hospital, Split, Croatia.
700    1_
$a Dworzak, Michael $u Children's Cancer Research Institute and St. Anna Children's Hospital, Vienna, Austria.
700    1_
$a Kaiserova, Emilia $u Department of Pediatric Oncology, University Children's Hospital, Bratislava, Slovakia.
700    1_
$a De Moerloose, Barbara $u Department of Pediatrics, Ghent University Hospital, Ghent, Belgium.
700    1_
$a Roula, Farah $u Department of Pediatrics, Saint George Hospital University Medical Centre, Beirut, Lebanon.
700    1_
$a Biondi, Andrea $u Department of Pediatrics, San Gerardo Hospital, University of Milano-Bicocca, Fondazione Monza e Brianza per il Bambino e la sua Mamma, Monza, Italy.
700    1_
$a Baruchel, André $u Department of Pediatric Hematology, Robert Debré Hospital, Paris, France.
700    1_
$a Guilhot, François $u INSERM Clinical Investigation Center 1402, Poitiers University, Poitiers, France.
773    0_
$w MED00001031 $t Cancer $x 1097-0142 $g Roč. 123, č. 18 (2017), s. 3609-3616
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28497898 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180516110510 $b ABA008
999    __
$a ok $b bmc $g 1300235 $s 1013451
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 123 $c 18 $d 3609-3616 $e 20170512 $i 1097-0142 $m Cancer $n Cancer $x MED00001031
LZP    __
$a Pubmed-20180515

Najít záznam

Citační ukazatele

Možnosti archivace